FDA authority to remove products from market would be undermined by S 1035, agency testifies.
This article was originally published in The Gray Sheet
FDA AUTHORITY TO REMOVE PRODUCTS FROM MARKET WOULD BE COMPROMISED by "The Access to Medical Treatment Act" (S 1035), FDA Executive Assistant to the Commissioner Jerold Mande asserted at a July 30 hearing on the bill before the Senate Labor and Human Resources Committee. The bill, sponsored by Minority Leader Tom Daschle (D-S.D.), would allow health practitioners to administer unapproved drugs, devices, foods or dietary supplements as long as there is no evidence that the treatment causes harm and the patient is informed about the treatment and its possible side effects.
You may also be interested in...
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.
RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.
The European Court of Justice rules that CBD cannot be regarded as a narcotic as it is non-psychoactive and suggests that a French ban on the cannabinoid is contrary to EU law on the free movement of goods. Legal experts and industry hope the judgment will pave the way for a regulated European CBD market.